In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sorrento Therapeutics, Inc.

https://sorrentotherapeutics.com/

Latest From Sorrento Therapeutics, Inc.

US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar

Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect

Commercial Sales & Earnings

Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes

Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.

Deals M & A

Chinese Newcomers Look For Niche Immuno-Oncology Opportunities

Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.

China ImmunoOncology

Location, Location, Location: Will Sorrento’s China-Only NSCLC Data Fly With US FDA?

Sorrento plans to meet with the US FDA regarding abivertinib, but the agency’s tough stance on drug approvals based on single-country studies could thwart the company’s efforts.

FDA China
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Saliva-based Testing
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • ADNAB, Inc.
    • Levena (Suzhou) Biopharma Co., Ltd
    • SCILEX Pharmaceuticals, Inc.
    • Scilex Holding Company
    • Scintilla Pharmaceuticals, Inc.
    • Semnur Pharmaceuticals, Inc.
    • Sherrington Pharmaceuticals
    • SmartPharm Therapeutics, Inc.
    • TNK Therapeutics, Inc.
    • Virttu Biologics Limited
UsernamePublicRestriction

Register